From Justin · PEDs & Compounds
Semaglutide monograph
Justin Harris — IFBB Pro Coach
From Justin
Semaglutide is a GLP-1 receptor agonist — the single-pathway version that retatrutide builds on. It's FDA-approved for diabetes and obesity, so it has a longer clinical track record than retatrutide, but the weight loss data shows it's less powerful than the triple agonist approach. The appeal is appetite suppression and scale weight through reduced hunger and slower gastric emptying. The downside is the same GI-heavy incretin class plus lean-mass loss if you under-eat and stop protecting protein and training. It is fat-loss pharmacology, not a bodybuilding compound. If someone is not obese or clearly metabolically indicated, the risk/benefit gets worse fast. Research-chem vials are not the clinical product. One possible side-benefit that may also be a side-effect, depending on the outcome, is the mesolimbic effects that can reduce alcohol cravings in addicts on the beneficial side, but negatively affect sexual expression on the lesser appealing side. GLP-1 is made in the gut and in hindbrain NTS neurons. About one third of those neurons project into VTA and nucleus accumbens, where GLP-1 receptors sit on reward circuitry. Agonism there shortens the extracellular dopamine signal. End result? Basal dopamine usually stays intact — alcohol-, cocaine-, amphetamine-, nicotine-, and food-evoked dopamine does not.
Semaglutide
Overview
Semaglutide is a long-acting GLP-1 receptor agonist used clinically for type 2 diabetes, obesity/weight management, cardiovascular risk reduction in select patients, and now noncirrhotic MASH with F2–F3 fibrosis for Wegovy injection. Its real value in coaching settings is appetite suppression, improved glycemic control, and easier calorie adherence—not a direct “fat burner.” The tradeoff is real GI burden and a non-trivial safety profile, so it belongs in medically supervised use, not casual experimentation. Weight loss still comes primarily from eating less — the same liraglutide-class rule — and if protein intake and resistance training are not protected, lean mass can fall with the fat.
Pharmacokinetics & Mechanism
- Class: GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist); long-acting incretin mimetic
- Mechanism of action: Semaglutide activates the GLP-1 receptor, increasing glucose-dependent insulin secretion, reducing glucagon release, slowing gastric emptying, and acting in central appetite/satiety pathways to reduce hunger and food intake.
- Target(s): Primary target: GLP-1 receptor (GLP1R). Downstream pathways include incretin-mediated glucose-dependent insulin secretion, reduced glucagon signaling, delayed gastric emptying, and central appetite/satiety circuitry in the hypothalamus and hindbrain. Semaglutide is protected from DPP-4 degradation and has high albumin binding, which prolongs exposure.
- Route(s) of administration: Subcutaneous injection (Wegovy, Ozempic) and oral tablet (Wegovy oral). The oral formulation requires fasting administration with limited water; injection is given subcutaneously in the abdomen, thigh, or upper arm.
- Onset: GI/appetite effects can begin within the first few weeks; clinical sources note many users notice fullness and reduced cravings by about week 4. Pharmacokinetically, subcutaneous Tmax is about 1 to 3 days post-dose, while oral semaglutide Tmax is about 1 hour post-dose.
- Half-life: Elimination half-life is approximately 1 week. Semaglutide remains in circulation for about 5 weeks after the last Ozempic dose and about 5 to 7 weeks after the last Wegovy 2.4/7.2 mg or oral 25 mg dose.
- Metabolism / clearance: Semaglutide is metabolized by proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid sidechain. Apparent clearance is about 0.05 L/h; excretion is mainly via urine and feces, with about 3% of dose recovered in urine as intact semaglutide. No clinically meaningful PK change is seen with renal or hepatic impairment in label data.
Members from here
The opener is free so Google can find us. The rest is how Justin actually uses it. That is the $29.99.
8 more minutes of this lecture, the full Troponin University library, and the TroponinIQ coach built on the same reasoning — one membership.
Keep reading
Source attribution
- [1]Troponin Nutrition knowledge base — Semaglutide